Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Rhythm Pharmaceuticals

Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone

This biotech stock is back in a buy zone after a sharp sell-off. The company makes an obesity drug and develops treatments for rare diseases.

Investors Business Daily

Stocks To Watch: Rhythm Pharmaceuticals Sees Relative Strength Rating Jump To 93

Rhythm Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Rhythm Pharmaceuticals is near a buy point after strong sales in the second quarter.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Enochian BioSciences (NASDAQ:ENOB) shares moved upwards by 27.8% to $2.3 during Wednesday's after-market session. The market value of their outstanding shares is at $121.7 million.

Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Benzinga

AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Rhythm Has Tripled In A Week And Quintupled Since May — Here's Why

Rhythm Pharmaceuticals has announced a steady drumbeat of good news for its obesity treatment, leading RYTM stock to triple in a week.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

33 Stocks Moving In Friday's Mid-Day Session

Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.

Benzinga

5 Analysts Have This to Say About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals (NASDAQ:RYTM) has observed the following analyst ratings within the last quarter:

Benzinga

Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug

The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).

Benzinga

Expert Ratings for Rhythm Pharmaceuticals

Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter:

Benzinga

Rhythm Pharmaceuticals's Return On Capital Employed Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) brought in sales totaling $1.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 23.09%, resulting in a loss of $52.76 million.

Benzinga

Rhythm Pharmaceuticals: Q1 Earnings Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Rhythm Pharmaceuticals Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET

Rhythm Pharmaceuticals (NASDAQ:RYTM) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Rhythm Pharmaceuticals (RYTM) Conference Call Follow this link to access the live webcast.

1 2

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.